{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 19,
  "pageCount": 58,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "industry_trends",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a dual-column layout to contrast market drivers (left) with specific regulatory examples (right).",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "callout_box",
    "footnote",
    "icon_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/19",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-19",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Stringent regulations and pharmas' commercial considerations are driving the development of truly innovative and differentiated therapies in China.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbc-c9f29040296c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.11,
        "y": 0.73
      },
      "kind": "list",
      "text": "CDE is raising the technical requirements for clinical development",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bc2299a-a632-4e5a-85aa-7ba3951c7f2d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.51,
        "y": 0.41
      },
      "kind": "list",
      "text": "If the drug fails to achieve desired effect in early clinical trials... decisions should be made in time to stop patient enrollment or terminate R&D of the drug. Drugs with uncertain safety / effectiveness or suboptimal drugs should not be selected as control.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42c4c6ac-5380-4fd2-a50f-edfb651803e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.51,
        "y": 0.73
      },
      "kind": "list",
      "text": "Unless a new mechanism is created through BsAb structure, otherwise, whether it is necessary for BsAb development should be considered carefully if other target already has druggability. If the BsAb targets include the mono therapy, it is required to include mono therapy from SoC** for the control group",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d3b007a-2afa-4aa3-a241-b5627b58fb5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.11,
        "y": 0.31
      },
      "kind": "list",
      "text": "Financial return is limited for drugs with fierce homogenous competition",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a098c86c-83dd-4226-b3af-f404b2ff337f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.11,
        "y": 0.52
      },
      "kind": "list",
      "text": "More difficult for homogenous drug asset to obtain financial funding",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8bb36d4-7bcf-44a5-ab00-0e9bfe8c3e52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.51,
        "y": 0.27
      },
      "kind": "paragraph",
      "text": "Guiding Principles for Clinical Value-Oriented Clinical Development of Oncology Drugs",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c00df9d-4f44-4097-b87e-925b99232d09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.51,
        "y": 0.59
      },
      "kind": "paragraph",
      "text": "Guiding Principles for Clinical Development of BsAb* Oncology Drugs (Draft for Comments)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f41975a3-5725-4054-b5c5-c6c5c7d38fb3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.28,
        "x": 0.038,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "Note: *BsAb: Bispecific Antibodies; **SoC: Standard of Care. Source: CDE, NMPA, Ping'An, L.E.K. research and analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23032ddd-5009-4956-901d-9de4a291f1f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.92,
        "x": 0.038,
        "y": 0.06
      },
      "kind": "title",
      "text": "Stringent regulations and pharmas' commercial considerations are driving the development of truly innovative and differentiated therapies in China",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a6c5eef-7258-4c1f-ad77-9a92a74bcbfd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.38,
        "x": 0.038,
        "y": 0.03
      },
      "kind": "title",
      "text": "Development of More Innovative and Differentiated Therapies",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "473a4a72-4cf2-4f55-8b0c-78724039799a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 12,
      "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f",
      "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.",
      "position": 0,
      "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}